Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
02616 CSTONE PHARMA-B
RTNominal down5.820 -0.360 (-5.825%)
Others

22/11/2021 10:40

CStone Pharma (02616) to grant exclusive rights to Hengrui

[ET Net News Agency, 22 November 2021] CStone Pharmaceuticals (02616) said the company
(CStone) and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui) announced a strategic
partnership and exclusive licensing agreement on anti-CTLA-4 mAb CS1002 in the Greater
China region. This strategic partnership marks another milestone in CStone's mission to
introduce innovative oncology therapies in China after the commercial launch of two
first-in-class drugs this year.
CStone granted the exclusive rights to Hengrui for research, development, registration,
manufacturing and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region.
CStone will retain the rights to develop and commercialize anti-CTLA-4 mAb CS1002 outside
of Greater China. CStone and Hengrui will partner respective R&D and commercial expertise
to accelerate the development and commercialization of anti-CTLA-4 mAb CS1002, a backbone
immuno-oncology asset, to fully unleash its commercial value.
Under the terms of the agreement, CStone will be eligible for an upfront payment and
potential milestone payments up to approximately US$200 million in addition to the
double-digit royalties. Hengrui will obtain the exclusive rights for research,
development, registration, manufacturing and commercialization of anti-CTLA-4 mAb CS1002
in Greater China. CStone will retain the rights to develop and commercialize of CS1002
outside of Greater China. (RC)

Remark: Real time quote last updated: 28/01/2022 17:04
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2022 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.